Browsing by Author "Sarmiento, Mauricio"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Autologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes
    (2023) Sarmiento, Mauricio; Rojas, Patricio; Gutierrez, Catherine; Quezada, Jacqueline; Jara, Veronica; Campbell, James; Maria, Garcia; Jose, Max; VicenteSandoval; Vergara, Max; Triantafilo, Nicolas; Ocqueteau, Mauricio
    This retrospective study shows the feasibility of performing autologous stem cell transplantation in lymphoma using a non-cryopreserved strategy with conventional conditionings administered in fewer days. In a cohort of 61 patients, benefits of avoiding DMSO cryopreservation were observed. Background: Hematopoietic autologous stem cell transplantation (ASCT) is a validated therapeutic strategy for lymphoma treatment and precise well-tolerated conditioning. Several conditioning methods are available, but the most commonly used are CVB, BEAM, and ICE, which are conventionally administered in 6 to 7 days. Since 2015, our program has moved toward noncr yopreser ved platforms that require concise times; therefore, we have modified the conditioning by reducing it to 4 to 5 days. In this study, we show our experience. Methods: We compared ASCT performed in our program before and after 2015 in lymphoma patients. Between 2000 and 2014 and from 2015 to 2022, we performed 46 and 61 ASCT procedures, respectively. Results: Since 2015, we observed a greater number of infused stem cells, fewer episodes of febrile neutropenia (60% vs. 37% P = .008), shorter hospitalizations (30 vs. 18 days P = .001), faster engraftment (20 vs. 14 days P = .001) and better progression-free survival (72 vs. 44 months P = .002). Additionally, a prolonged overall survival was observed at these results, and this prolonged survival is difficult to interpret due to the short follow-up. Conclusion: In conclusion, conditioning adjusted for a noncryopreserved strategy offers at least similar or even better results than the cr yopreser ved strategy. Prospective studies are warranted.
  • Thumbnail Image
    Item
    Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial
    (2020) Balcells, María Elvira ; Rojas, Luis ; Le Corre, Nicole ; Martínez-Valdebenito, Constanza ; Ceballos, María Elena ; Ferrés, Marcela ; Chang, Mayling ; Vizcaya, Cecilia ; Mondaca, Sebastián ; Huete, Álvaro ; Castro, Ricardo ; Sarmiento, Mauricio ; Villarroel, Luis ; Pizarro, Alejandra; Ross, Patricio ; Santander, Jaime ; Lara, Barbara ; Ferrada, Marcela ; Vargas-Salas, Sergio ; Beltrán-Pavez, Carolina ; Soto-Rifo, Ricardo ; Valiente-Echeverría, Fernando ; Caglevic, Christian ; Mahave, Mauricio ; Selman, Carolina ; Gazitúa, Raimundo ; Briones, José Luis ; Villarroel-Espindola, Franz ; Balmaceda, Carlos ; Espinoza, Manuel A. ; Pereira, Jaime ; Nervi, Bruno
  • No Thumbnail Available
    Item
    Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies
    (2020) Sarmiento, Mauricio; Ramirez, Pablo; Jara, Veronica; Bertin, Pablo; Galleguillos, Mauricio; Rodriguez, Isabel; Lorca, Carla; Pizarro, Isabel; Rivera, Elizabeth; Ocqueteau, Mauricio
    Introduction: Patients with benign or malignant blood disorders, who require allogeneic stem cell transplantation and lack an identical human leukocyte antigen HLA identicalHL sibling donor, could be transplanted with hematopoietic stem cells from unrelated adult or umbilical cord donors. However, in our country, both approaches are costly and time-consuming options.
  • No Thumbnail Available
    Item
    Kinetic of humoral response induced by SARS-CoV-2 infection in convalescent plasma receptors and donors
    (WILEY, 2021) Barrera, Aldo; Martinez Valdebenito, Constanza; Rojas Orellana, Luis; Vizcaya Altamirano, Cecilia; Elena Ceballos, Maria; Pereira, Jaime; Chang, Mayling; Mondaca, Sebastian; Sarmiento, Mauricio; Ross, Patricio; Henriquez, Carolina; Nervi, Bruno; Ferres, Marcela; Balcells, Elvira; Le Corre, Nicole
  • No Thumbnail Available
    Item
    Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids
    (2021) Sarmiento, Mauricio; Rojas, Patricio; Jerez, Joaquin; Bertin, Pablo; Campbell, James; Garcia, Maria J.; Pereira, Jaime; Triantafilo, Nicolas; Ocqueteau, Mauricio
    Introduction: Currently, severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is a major public health problem worldwide. Although most patients present a mild infection, effective strategies are required for patients who develop the severe disease. Anti-inflammatory treatment with JAK inhibitors has been considered in SARS-CoV-2. Methods: In this study, we presented our experience in a group of severe SARS-CoV-2 Chilean patients. This prospective study was performed on consecutive patients presenting severe respiratory failure owing to COVID-19 or high-risk clinical condition associated with SARS-CoV-2, and who were treated with ruxolitinib for management of associated inflammation. Overall, 18 patients presenting SARS-CoV-2 viral-induced hyperinflammation were treated with ruxolitinib, with 16 patients previously treated with steroids, 4 with tocilizumab, and 3 with both treatments. Results: Ten patients evolved with favorable response, including 7 patients admitted with severe respiratory failure (PaFi less than 200 mm Hg in high-flow nasal cannula), presenting complete regression of hyperinflammation, regression of the lung lesions, and subsequent discharge. In the remaining 8 patients, 25% showed reduced inflammation, but early discharge was not achieved owing to the slow evolution of respiratory failure. Unfortunately, 3 patients demonstrated a severe respiratory failure. The early initiation of ruxolitinib was found to be associated with better clinical evolution (p < 0.005). Conclusion: In this study, ruxolitinib resolved hyperinflammatory state in 55% of the patients, regardless of the previous steroid or tocilizumab therapy. Unfortunately, few patients demonstrated severe evolution despite ruxolitinib therapy. Notably, the treatment starting time appears to play an important role in achieving good outcomes. Further validation in randomized controlled trials is crucial.